Click here to close now.




















Welcome!

News Feed Item

MusclePharm Reports 2014 Second-Quarter Financial Results

Second-Quarter Revenue Increases to $46.7 Million With Earnings of $0.03 per Diluted Share

DENVER, CO -- (Marketwired) -- 08/04/14 -- MusclePharm Corporation (OTCQB: MSLP), a scientifically driven, performance-lifestyle sports nutrition company, today announced financial results for the second quarter ended June 30, 2014.

2014 Second-Quarter Results

The following comparison refers to results for the second quarter of 2014 versus the second quarter of 2013.

Net sales increased 83 percent to $46.7 million from $25.5 million last year, primarily as a result of new sales channels, new product lines, and increased brand awareness.

Net sales by distribution channel were as follows:

  • Food, Drug and Mass (FDM), a new distribution channel for MusclePharm in 2014, accounted for $5.0 million of the Company's sales increase;

  • International increased $10.7 million, or 119 percent, to $19.7 million, compared with $9.0 million during the same period last year; and,

  • Specialty, which includes distributors and online retailers, grew by $2.6 million, or 16 percent, to $19.0 million, compared with $16.4 million last year.

Gross profit was $15.6 million, compared with $7.9 million last year. As a percentage of net sales, gross profit was 33.5 percent, compared with 31.1 percent last year.

Operating expenses as a percentage of net sales decreased to 32.5 percent, compared with 41.8 percent last year.

Net income was approximately $400,000, or $0.03 per diluted share, compared with a net loss of approximately $2.4 million, or $0.34 per share, for the same period last year.

"MusclePharm's solid second-quarter results are a testament to the strength of the company's brands in what has historically been a challenging quarter," said Brad Pyatt, MusclePharm's chairman and chief executive officer. "As MusclePharm gains further traction both domestically and internationally, we remain focused on driving the strength of our brands, while enhancing our leadership position."

Recent Highlights

  • Launched more than 60 new items within the MusclePharm® Hybrid and Core Series, Arnold Schwarzenegger Series™ and FitMiss™ brands, including new products, new flavors and new sizes in the second quarter. MusclePharm has launched more than 100 new items year-to-date;
  • Signed a multi-year endorsement agreement with Tiger Woods, which includes sponsorship of Tiger Woods' golf bag. The 2014 Open Championship was viewed by 7.45 million people with MusclePharm's logo legible 72 percent of the time Tiger's golf bag appeared on-screen. Total bag exposure was more than an hour and twenty minutes;
  • Signed a multi-year endorsement contract with Johnny Manziel;
  • Expanded relationship with GNC to carry all of MusclePharm's brands on a dedicated wall in all of GNC's U.S. stores;
  • Published the results of a double-blind placebo-controlled clinical study, which demonstrated that MusclePharm's recovery and hydration supplement Amino1 enhanced rehydration more effectively than water and Gatorade. MusclePharm plans on conducting approximately 20 clinical studies during the year;
  • Received 25 nominations for the 2014 Bodybuilding.com Supplement Awards. Categories for consideration include the prestigious Brand of the Year award for both the MusclePharm and Arnold Schwarzenegger brands. Nominees were chosen based on sales performance on Bodybuilding.com; and,
  • Added Gregory Macosko to the Board of Directors and named him as Chairman of the Audit Committee. Macosko is also on the Board of Montrose Advisors and is a retired partner and portfolio manager of Lord Abbet's Small Cap Value Fund.

2014 Six-Month Results

The following comparison refers to results for the first six months of 2014 versus the first six months of 2013.

Net sales increased 102 percent to $96.9 million from $48.0 million last year.

Net sales by distribution channel were as follows:

  • Food, Drug and Mass (FDM), a new distribution channel for MusclePharm in 2014, accounted for $10.2 million of the Company's sales increase;

  • International increased $22.7 million, or 148 percent, to $38.0 million compared with $15.3 million during the same period last year; and,

  • Specialty, which includes distributors and online retailers, grew by $10.6 million, or 33 percent, to $42.8 million compared with $32.2 million last year.

Gross profit was $33.5 million, compared with $16.1 million last year. As a percentage of net sales, gross profit was 34.6 percent, compared with 33.5 percent last year.

Operating expenses as a percentage of net sales decreased to 31.6 percent, compared with 40.7 percent last year.

Net income was approximately $3.1 million, or $0.27 per diluted share, compared with a net loss of approximately $9.8 million, or $1.72 per share, for the same period last year.

At June 30, 2014, the company had approximately $3.8 million in cash.

2014 Full-Year Guidance

MusclePharm is increasing its full-year guidance for 2014 as follows:

  • 2014 full-year net sales of approximately $185 to $195 million

  • Diluted earnings per share in the range of $0.45 - $0.50

MusclePharm has provided this outlook based on assumptions of weighted average diluted shares outstanding of 12.6 million for the year.

"With new and growing retail relationships, an increased international presence, and development of additional brands, products and extensions backed by some of the world's most accomplished athletes, we believe that MusclePharm is emerging as a lifestyle brand that has broad and diverse appeal," Pyatt added.

2014 Second Quarter Conference Call Information

When:      Tuesday, August 5
Time:      8:30 a.m. Eastern Time
Phone:     1-877-407-9126 (domestic)
           1-201-493-6751 (international)

A live webcast will be available online on MusclePharm's website at http://ir.musclepharmcorp.com, where it will be archived for one year.

An audio replay of the conference call will be available through midnight August 12 by dialing 877-407-9126 from the U.S. or Canada, or 201-612-7415 from international locations, passcode 13581597.

About MusclePharm

MusclePharm® is a scientifically driven, performance-lifestyle company that currently develops, manufactures, markets and distributes branded nutritional supplements. The company offers a complete range of powders, capsules, tablets and gels. Its portfolio of recognized brands, including MusclePharm® Hybrid and Core Series, Arnold Schwarzenegger Series™ and FitMiss™, are marketed and sold in more than 110 countries and available in more than 35,000 retail outlets globally. These clinically-proven and scientific nutritional supplements are developed through a six-stage research process utilizing the expertise of leading nutritional scientists, doctors and universities. We believe that MusclePharm is the innovator of the sports nutrition industry. For more information, visit www.musclepharm.com.

Follow the company at http://www.facebook.com/MusclePharm and www.Twitter.com/MusclePharm

To sign up to receive MusclePharm news via email, please visit http://ir.musclepharmcorp.com/email-alerts

Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.



                          MusclePharm Corporation
                       Condensed Financial Statements

                                                 For the Three Months Ended
                                                          June 30,
                                                         (unaudited)
                                                 --------------------------
                                                     2014          2013
                                                 ------------  ------------
Net sales                                        $ 46,739,987  $ 25,480,059
Cost of goods sold                                 31,093,224    17,566,718
                                                 ------------  ------------
Gross profit                                       15,646,763     7,913,341
Operating expenses                                 15,167,248    10,654,272
                                                 ------------  ------------
Income (loss) from operations                         479,515    (2,740,931)
Other income (expense)                                (71,187)      319,123
                                                 ------------  ------------
Net income (loss)                                $    408,328  $ (2,421,808)
                                                 ============  ============

Earnings per share - basic                       $       0.04  $      (0.34)
Earnings per share - diluted                     $       0.03  $      (0.34)

                                                  For the Six Months Ended
                                                          June 30,
                                                         (unaudited)
                                                 --------------------------
                                                     2014          2013
                                                 ------------  ------------
Net sales                                        $ 96,949,441  $ 48,041,226
Cost of goods sold                                 63,429,609    31,963,124
                                                 ------------  ------------
Gross profit                                       33,519,832    16,078,102
Operating expenses                                 30,616,428    19,540,512
                                                 ------------  ------------
Income (loss) from operations                       2,903,404    (3,462,410)
Other income (expense)                                241,158    (6,321,379)
                                                 ------------  ------------
Net income (loss)                                $  3,144,562  $ (9,783,789)
                                                 ============  ============

Earnings per share - basic                       $       0.30  $      (1.72)
Earnings per share - diluted                     $       0.27  $      (1.72)



                           MusclePharm Corporation
                       Condensed Financial Statements
                                                                December 31,
                                                 June 30, 2014      2013
                                                  (unaudited)    (audited)
                                                 ------------- -------------
                     Assets
Current assets                                   $  50,547,702 $  44,526,480
Property and equipment - net                         6,221,261     2,613,584
Intangible assets - net                              6,732,532       155,165
Other assets                                         3,431,423     4,862,467
                                                 ------------- -------------
Total assets                                     $  66,932,918 $  52,157,696
                                                 ============= =============
      Liabilities and Stockholders' Equity
Current liabilities                                 28,473,117    32,368,521
Long term liabilities                                  366,378        54,639
                                                 ------------- -------------
Total liabilities                                   28,839,495    32,423,160
Total stockholders' equity                          38,093,423    19,734,536
                                                 ------------- -------------
Total Liabilities and Stockholders' Equity       $  66,932,918 $  52,157,696
                                                 ============= =============

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
With SaaS use rampant across organizations, how can IT departments track company data and maintain security? More and more departments are commissioning their own solutions and bypassing IT. A cloud environment is amorphous and powerful, allowing you to set up solutions for all of your user needs: document sharing and collaboration, mobile access, e-mail, even industry-specific applications. In his session at 16th Cloud Expo, Shawn Mills, President and a founder of Green House Data, discussed h...
For IoT to grow as quickly as analyst firms’ project, a lot is going to fall on developers to quickly bring applications to market. But the lack of a standard development platform threatens to slow growth and make application development more time consuming and costly, much like we’ve seen in the mobile space. In his session at @ThingsExpo, Mike Weiner, Product Manager of the Omega DevCloud with KORE Telematics Inc., discussed the evolving requirements for developers as IoT matures and conducte...
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities.